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Background: Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in approximately
20% of invasive breast cancer cases and is associated with a more aggressive disease course than HER2-negative
breast cancer. HER2-targeted therapies have altered the natural history of HER2-positive breast cancer, a trend that
will likely further improve with the recent approval of new agents. A prospective, observational cohort study was
designed and initiated to provide real-world insights into current treatment patterns, long-term survival, and
patients’ experiences with initial and subsequent treatments for HER2-positive metastatic breast cancer (MBC).
Methods/Design: The Systematic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs) is a US-based
prospective observational cohort study enrolling patients ≥18 years of age with recently diagnosed HER2-positive MBC
not previously treated with systemic therapy in the metastatic setting. The primary objective of the study is to identify
treatment patterns and clinical outcomes in recently diagnosed patients in a variety of practice settings. Secondary
objectives include comparative efficacy, safety, and patient-reported outcomes (PROs). Healthcare resource utilization
is an exploratory end point. Tumor tissue and blood sample collection is optional.
The SystHERs registry will enroll approximately 1000 patients over a 3-year period, after which the study will continue
for ≥5 years, allowing for a maximum follow-up of 8 years. The treating physician will determine all care and the
frequency of visits. PRO measures will be completed at study enrollment and every 90 days. Clinical data will be
abstracted quarterly from patient records. The first patient was enrolled in June 2012, and preliminary descriptive
data based on 25% to 30% of the final study population are expected at the end of 2013, and as of April 25, 2014,
386 patients are enrolled.
Discussion: SystHERs is expected to provide in-depth data on demographic, clinicopathological, and treatment
patterns and their associations with clinical outcomes, PROs, and healthcare resource utilization. Tumor tissue
and DNA repositories will also be established for use in future translational research.
Trial registration number: NCT01615068 (ClinicalTrials.gov identifier).
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The successful development of targeted agents for can-
cer therapy represents a major advance in personalized
medicine, which strives to maximize therapeutic benefit
while minimizing harmful side effects. In the field of
breast cancer, human epidermal growth factor receptor
2 (HER2)–targeted therapies provide early examples of
effective personalized medicine. The HER2 gene is amp-
lified in approximately 20% of invasive breast cancer
cases [1,2], and this amplification is associated with an
aggressive disease course [1,3]. To date, four HER2-
targeted agents have received approval from the US
Food and Drug Administration (FDA) for the treatment
of patients with advanced HER2-positive breast cancer.
Three of these agents have been approved in com-
bination with chemotherapy: trastuzumab (a human-
ized monoclonal antibody that targets subdomain IV of
HER2), lapatinib (a HER1/HER2 dual tyrosine kinase
inhibitor), and, in combination with trastuzumab, per-
tuzumab (a humanized monoclonal antibody that tar-
gets domain II of HER2 [ie, the dimerization domain],
thereby inhibiting receptor dimerization and subsequent
signaling. Trastuzumab emtansine (T-DM1), an antibody-
drug conjugate comprising the cytotoxic agent DM1 joined
with a stable linker to trastuzumab, has been approved as a
single-agent (Figure 1).
Prior to the advent of HER2-targeted therapy, the
prognosis for patients with HER2-positive breast cancer
was markedly worse than it was for patients with HER2-
negative disease [1]. Since trastuzumab was approved for
the treatment of metastatic breast cancer (MBC) by theFigure 1 Timeline of FDA approvals of HER2-targeted breast cancer th
studies. BC, breast cancer; FDA, US Food and Drug Administration; HER2, hu
cancer; OS, overall survival; SystHERs, Systematic Therapies for HER2-positiveFDA in 1998, patients with HER2-positive disease treated
with HER2-targeted therapy now have a better prognosis
than patients with HER2-negative disease receiving stand-
ard treatment [2].
The treatment paradigm for HER2-positive MBC
continues to evolve as breast cancer is recognized as a
heterogeneous disease with multiple phenotypes. Even
within the same tumor, heterogeneity in gene expression
can create challenges for identifying molecular targets for
therapy, resulting in primary and acquired tumor resist-
ance [4], which may explain, at least in part, the variable
activity of targeted therapies [5,6]. On the basis of the re-
sults of a number of studies that have assessed therapies
following progression on trastuzumab [7-12], it has been
suggested that the ongoing blockade of HER2 leads to
improved outcomes. This and new insights into growth
factor receptor pathways continue to spur the develop-
ment of novel HER2-targeted therapies. Future directions
in the treatment of HER2-positive MBC may involve
chemotherapy-free combined biologic treatment ap-
proaches in an effort to overcome tumor resistance and
increase tolerability of treatment. This concept was dem-
onstrated in a randomized trial with dual blockade using
trastuzumab and lapatinib compared with lapatinib alone
following exposure to trastuzumab [10], as well as in a
phase II study showing activity of pertuzumab plus tras-
tuzumab [13]. The CLEOPATRA study was a phase III
randomized controlled trial that demonstrated improved
progression-free survival (PFS) and overall survival (OS) in
patients with metastatic HER2-positive breast cancer when
pertuzumab was added to trastuzumab plus docetaxelerapies and conduct of the registHER and systHERs observational
man epidermal growth factor receptor 2; MBC, metastatic breast
Metastatic Breast Cancer Study; T-DMI, trastuzumab emtansine.
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for predicting response to individual therapies will also be
important [6,16].
The changing therapeutic landscape for patients with
HER2-positive MBC provides multiple options and op-
portunities for these patients, but it also increases the
complexity of clinical decision making. Physicians must
take into account factors such as the optimal sequencing
of treatments to achieve the best overall clinical and sur-
vival outcomes while also minimizing toxicity. Data from
randomized clinical trials and treatment guidelines from
agencies such as the National Comprehensive Cancer
Network can help inform treatment decisions. However,
since real-world patients with MBC often have very dif-
ferent characteristics than those enrolled in clinical tri-
als, clinicians often must extrapolate best practices into
therapeutic decisions in later lines of therapy for patients
who maintain good performance status and are candi-
dates for further therapy. Furthermore, as treatments
evolve, it becomes difficult to conduct randomized con-
trolled trials of all potential therapies and their combi-
nations. Prospective observational studies represent an
important complement to randomized controlled trials;
they can offer insight into treatment patterns and long-
term survival in much less selective patient populations.
They can also provide data on comparative effectiveness
of treatment regimens. In the United States, population-
based data on MBC are available through several na-
tional programs and registries such as the Surveillance
Epidemiology and End Results program and the Breast
Cancer Family Registry. However, data from these sources
often do not provide detailed information on evolving
treatment regimens, practice patterns, therapeutic efficacy,
or toxicities.
One US population–based prospective observational
study of patients with HER2-positive breast cancer
has been carried out. This multicenter registry study,
registHER, enrolled 1023 patients with recently diag-
nosed HER2-positive MBC from December 2003 to
February 2006, and followed patients until early 2009,
or until death/discontinuation from the study. The ob-
jectives of registHER were to describe disease natural
history and treatment patterns in patients with HER2-
positive MBC, as well as the associations between specific
treatments and patient outcomes [17]. Overall, 87% of
patients were treated with trastuzumab in the first-line
setting, and median survival from the time of MBC diag-
nosis was longer in patients treated with trastuzumab in
their first-line treatment regimen than in those treated
without first-line trastuzumab (35.9 versus 31.4 months)
[18]. Another important finding from registHER was that
in a multivariate model adjusting for prognostic factors
(Eastern Cooperative Oncology Group performance status,
hormone receptor status, site of first disease progression),the risk of death was decreased in patients who contin-
ued to receive trastuzumab after their first disease pro-
gression compared with those who did not (adjusted
hazard ratio, 0.23; 95% confidence interval, 0.17–0.31)
[18]. Furthermore, first-line treatment with a trastuzumab-
containing regimen was associated with better OS and PFS
in patients with HER2-positive/hormone receptor–positive
MBC [19], improved PFS across all age groups [20], and
longer OS in patients with central nervous system metas-
tases [17,20]. Biological insights into the heterogeneity of
this populations emerged when it was demonstrated that
patients presenting with de novo compared with recur-
rent metastatic disease had a longer median survival [21].
Also, a latent class modeling approach revealed two bio-
logically distinct groups of patients with widely diverging
survival [22].
Since the closure of registHER enrollment in 2006, the
treatment portfolio for HER2-positive MBC has changed
significantly, with lapatinib, pertuzumab and T-DM1 ap-
proved for use in the metastatic setting (see Figure 1)
[8,14,23]. Furthermore, since trastuzumab was first ap-
proved for adjuvant use in 2006, fewer patients treated
in the adjuvant setting develop recurrent metastatic dis-
ease. Treatment with trastuzumab in the adjuvant set-
ting may also affect the natural history and effect of
subsequent therapies [6,24-26]. Set against the backdrop
of evolving therapeutic options for HER2-positive MBC,
the Systematic Therapies for HER2-Positive Metastatic
Breast Cancer Study (SystHERs) has been established to
address gaps in our knowledge about which treatments
are chosen and administered to patients with HER2-
positive MBC, the corresponding outcomes, and the pa-
tients’ perspectives on their experience over the course
of their disease. The collected data will reflect currently
available HER2-directed therapies in a real-world setting,
as well as the costs associated with these therapies. The
study has also been designed to collate pharmacovigi-
lance data to allow for the detection and characterization
of any new safety signals. Finally, a tissue repository will
be created as part of this study, thereby providing a ro-
bust resource for future translational research.
Methods/Design
SystHERs (ClinicalTrials.gov; NCT01615068) is a US-
based, multicenter, prospective, observational cohort study.
Its primary objective is to describe temporal trends in
treatment patterns, the sequencing of treatments upon
progression, and clinical outcomes (PFS, OS, key toxicities)
in patients with HER2-positive MBC. Patients will undergo
treatment and assessments in accordance with their treat-
ing physician’s standard practice; there is no study proto-
col–specified treatment regimen or evaluation schedule.
The registry is enrolling patients within 6 months of their-
diagnosis of HER2-positive MBC. The first patient was
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to 8 years. A total of 121 study sites are currently active.
Patient flow through the study at screening/baseline is
illustrated in Figure 2.
Eligibility criteria
The registry is enrolling patients ≥18 years old with an
initial diagnosis of HER2-positive MBC using physicians’
and institutional standards (based on the status of the
primary tumor or biopsy of recurrence) within 6 months
of the time of enrollment. Eligible patients must also
have cancer-specific historical data points in their med-
ical records. The only exclusion criteria for SystHERs
are (1) any inability to provide informed consent and
(2) diagnosis of HER2-positive MBC more than 6 months
before enrollment. The inclusion criteria for SystHERs are
intentionally broad in an effort to exclude as few patients
as possible and thereby capture true population-based
data.
Ethical considerations
All participating patients must provide written informed
consent and authorization to use their medical records;Figure 2 Patient flow through the SystHERs registry at baseline. BC, b
undiagnosed metastatic breast cancer; ECOG PS, Eastern Cooperative Onco
receptor 2; recurrent disease, first detection of metastases >90 days following
Therapies for HER2-positive Metastatic Breast Cancer Study; TNM, tumor–nodeparticipation in translational research (ie, collection of
blood and tissue for the DNA and tumor tissue reposi-
tories, respectively) is optional, and each requires separ-
ate consent. To maintain patient confidentiality, all
patient-identifying information will be removed from tis-
sue and blood samples prior to analysis, and it will there-
fore not be possible to link specific samples with their
patient source. The study is being conducted in accord-
ance with FDA regulations, the International Conference
on Harmonization E6 Guidelines for Good Clinical
Practice, the Declaration of Helsinki, and applicable local
laws. Ethical approval has been obtained from all partici-
pating study sites in the form of written approval of the
study protocol by the ethics committee or institutional
review board at each site.
Baseline evaluation and follow-up
Baseline patient and tumor characteristics, disease his-
tory, HER2 testing methodology, and previous cancer-
related treatment data (including prior treatments for
early-stage disease) are collected at enrollment. Subse-
quently, data on changes in cancer-related treatment, clin-
ical outcomes, and adverse events (AEs) will be abstractedreast cancer; CRFs, case report form; de novo disease, previously
logy Group performance status; HER2, human epidermal growth factor
histological diagnosis of early-stage breast cancer; SystHERs, Systematic
–metastasis.
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and laboratory findings. This includes tumor assessment
(complete response, partial response, stable disease, pro-
gressive disease, unevaluable), method of tumor assess-
ment, and sites of progression or new metastases. HER2,
estrogen receptor, and progesterone receptor status is
captured at both initial diagnosis and MBC recurrence.
Patient-reported outcomes (PROs) are collected at study
enrollment and every 90 days (Table 1).
Study end points
Primary end point: treatment patterns and sequencing
The primary end point is the distribution of patients
receiving unique treatment regimens or a sequence of
treatment regimens for HER2-positive MBC.Table 1 Timing of data assessments in the SystHERs registry





Cardiovascular risk factors X
Other relevant medical history X
Selected concomitant medications Xb
Selected laboratory tests X
Breast cancer–specific cancer history Xc
Prior cancer treatment history X
Healthcare resource utilization X
Healthcare provider type X
Insurance coverage and provider X
PROsd X





Interval hormonal therapy history
Protocol-specified AEsh
Study discontinuation reason (including death)
aPatient data should be reported at the time of study termination.
bAll breast cancer treatments (including neoadjuvant and adjuvant treatments and
specified safety events, will be recorded.
cTo include stage (at time of diagnosis), histology, estrogen receptor/progesterone
absence of central nervous system metastases.
dPROs will be collected during clinic visits at approximately 90-day intervals (±15 da
(see Table 2 for details of PROs).
eAn attempt will be made to collect PROs at study discontinuation.
fConsent is required for collection of blood and tissue samples. Blood and/or tissue
gSites of disease progression and new metastatic sites will be recorded.
hThese include all SAEs, selected AEs, AEs of special interest, and AEs/SAEs that lead
must be reported to Genentech within 24 hours of learning of the events.
AE, adverse event; PRO, patient-reported outcome; SAE, serious adverse event; STIA
Systematic Therapies for HER2-Positive Metastatic Breast Cancer Study.Secondary end points: clinical efficacy and safety
Secondary objectives of this study include comparing
the efficacy and safety of HER2-targeted treatment
regimens and evaluating the associations between pa-
tient characteristics, treatment variables and efficacy
outcomes. Secondary clinical efficacy end points for
this study are investigator-assessed PFS, OS, post-
progression survival (measured once per patient, as
the time from first investigator-assessed disease pro-
gression to death from any cause), time to treatment
failure (ie, time from start of first-line HER2-targeted
treatment to date of investigator-assessed disease pro-
gression, treatment discontinuation due to toxicity or
death from any cause), and response rate (ie, proportion
of patients with complete response or partial responseon















duration) and select concomitant treatments, including those for protocol-
receptor status, metastatic sites, staging diagnostic work-up, presence or
ys) and at frequent intervals to capture PRO data around disease progression
sample(s) can be collected at any time while on study.
to treatment discontinuation or modification. SAEs, pregnancies, and STIAMPs
MP, suspected transmission of infectious agent by medicinal product, SystHERs,
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assessed disease progression may be based on clinical
examination or radiographic or laboratory features,
mirroring routine practice. All study assessments, includ-
ing tumor response assessments, will be performed in
accordance with institutional guidelines.
Safety end points are the incidences of serious AEs
(SAEs), nonserious selected AEs, AEs/SAEs leading to
treatment discontinuation or modification, and AEs of
special interest (including pregnancy and suspected
transmission of infectious agent by medicinal product
[STIAMP]). SAEs are to be reported within 24 hours
of the investigators’ awareness, while other AEs are to
be graded using Common Terminology Criteria for
Adverse Events (CTCAE) v4.0 and reported at quarterly
data updates.
Selected AEs are cardiac dysfunction (≥1 of the follow-
ing: left ventricular systolic dysfunction, congestive heart
failure, cardiac arrest, cardiac ischemia/infarction), hep-
atotoxicity (severe drug-induced liver injury, nodular re-
generative hyperplasia of the liver), thrombocytopenia
associated with bleeding, infusion-related reactions/
hypersensitivity, pulmonary events (pneumonitis, adult
respiratory distress syndrome, interstitial lung disease),
and CTCAE, v4.0, grade ≥3 febrile neutropenia [27].
Secondary end points: PROs
Another secondary objective of this study is to examine
the association between HER2-targeted treatment regi-
mens (and their sequencing) with PROs. Selection of
PROs was based on a literature review, feedback from
clinical experts, and the guidance document by Basch
et al. regarding the incorporation of PROs in compara-
tive effectiveness research in adult oncology [28]. Eight
PRO measures are included that span a broad range of
patient experiences such as symptom burden, ability to
perform activities of daily living, and work productivity.
Data from the following PRO assessments (Table 2)
are collected in self-completed questionnaires at 90-day
intervals (approximately) during clinic visits: Overall
Health Related Quality-of-Life Question [Genentech, data
on file], Functional Assessment of Cancer Therapy-Breast
[29], alopecia patient assessment for patients with alopecia
[Genentech, data on file], Patient Neurotoxicity Ques-
tionnaire [30], the MD Anderson Symptom Inventory
Brain Tumor Module (only items related to cognitive
function and interference with daily functioning) [31],
Rotterdam Symptom checklist (only items relating to
activities of daily living) [32], Work Productivity and
Activity Impairment-Specific Health Problem question-
naire [33] (unemployed patients will answer two items),
and the Health Care Survey (collects information on
hospitalizations, emergency room visits, and out-of-
pocket expenses) [Genentech, data on file]. Out-of-pocketexpenses include co-payments, deductibles, transportation,
and costs related to health care visits, as described previ-
ously [34]. It is estimated that patients will take 25 minutes
to complete these quarterly PRO assessments. While
it is preferred that this be performed at the physician’s
office through an online interface using an iPad® (Apple
Corp., Cupertino, CA), patients will also have the abil-
ity to complete the PROs at home using their own
computer. Electronic capture of data will allow for rapid
Web-based entry and will minimize difficulties inherent
in the process of data transfer from paper to electronic
databases.
Patients are compensated every quarter for completing
the PRO instruments in an effort to offset costs associ-
ated the extra time required of patients.
Exploratory end points
Exploratory objectives of the study include health eco-
nomic assessment and translational research. Health
economic assessment will be captured by means of the
Health Care Survey described in the previous section.
For the exploratory objective of future translational re-
search, the study protocol includes the optional collec-
tion of tumor tissue (including biopsies of metastatic
sites if done as part of routine clinical care at the re-
spective clinical site) for storage in a central tissue bank,
as well as whole blood collection (at any time during the
study) and subsequent DNA extraction for storage in a
central DNA repository. Tissue samples may be in the
form of paraffin-embedded primary tumor blocks from
which cores may be taken to create tissue microarrays or
up to 15 unstained microscope slides cut from those
blocks. If whole tumor blocks cannot be donated to the
repository, 6 to 8 cores can be taken from the sample
for tissue microarrays and the reminder of the block
returned to the site. Tissue and DNA samples may be
stored and analyzed for up to 15 years after completion
of the study. It is anticipated that this biospecimen re-
pository will use high throughput technologies for gene
expression analyses, genomic sequencing, identification
of copy number/rearrangements, epigenetic status, and
select protein analyses, permitting the identification of
predictors of treatment response, long-term survival,
and safety.
The patient data examined in this study will also en-
able the possible exploration of treatment compliance
patterns. In particular, the source data include hospital
records, clinical and office visit charts, and pharmacy
dispensing records. Together, these sources will allow
documentation of dose reductions of anticancer therap-
ies, as well as the number of doses delivered. Collection
of AE data and reasons for study discontinuation will
enhance the interpretation of dose reductions and the
duration and discontinuation of therapy.
Table 2 Key features of patient-reported outcome (PRO) scales used in the SystHERs registry
PRO instrument Key features Frequency of
administration
Overall Health Related Quality of Life (HRQOL) question Single question: “On a scale of 0–100, how would you rate
your quality of life today?”
Every 90 days
Functional Assessment of Cancer Therapy-Breast
(FACT-B) [29]
Self-report instrument designed to measure multidimensional
QOL in patients with breast cancer
Every 90 days
Alopecia patient assessment For use only in patients with alopecia; developed by
Genentech
Every 90 days
Patient Neurotoxicity Questionnaire (PNQ) [30] Assesses neurosensory and neuromotor symptoms on
activities of daily living
Every 90 days
MD Anderson Symptom Inventory Brain Tumor Module
(MDASI-BT) [31]
Only items related to cognitive functioning and interference
with daily functioning will be administered
Every 90 days
Rotterdam Symptom Checklist [32] Self-report instrument to measure QOL in cancer patients.
Only items related to activities of daily living will be
administered
Every 90 days
Work Productivity and Activity Impairment-Specific
Health Problem (WPAI-SPH) questionnaire [33]
Patient-reported quantitative assessment of the amount of
absenteeism, presenteeism, and daily activity impairment
attributable to a specific health problem (breast cancer);
unemployed patients will answer only 2 questions
Every 90 days
Health Care Survey Quantifies hospitalizations, emergency room visits, and
out-of-pocket expenses; developed by Genentech
Every 90 days
MBC, metastatic breast cancer; QOL, quality of life.
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SystHERs has a planned enrollment of approximately
1000 patients and a recruitment period of approximately
3 years. Subsequent to full accrual, the study will continue
for at least 5 years, allowing for a maximum follow-up
period of 8 years.
To minimize selection bias, enrolling centers are being
asked to systematically invite all eligible patients to par-
ticipate in the study. Potential selection bias will be eval-
uated by gathering limited data (reason not enrolled, age
range, race, disease-free interval, and performance status)
on patients who meet all inclusion criteria but who are not
enrolled.
Electronic data capture
Patient clinical data and limited healthcare resource
utilization data will be obtained from patients’ medical
records via a Web-based password-protected/HIPAA
compliant data collection system using electronic case
report forms. The contract research organization will
be responsible for the data management of this study,
including quality checking the data, with Genentech
performing oversight of the data management. System
backups for data stored at Genentech and records
retention for the study data will be consistent with
Genentech’s standard procedures. PROs (including self-
reported healthcare resource utilization data) will be col-
lected on site approximately every 90 days throughout
the study during clinic visits that are determined by the
treating physician. However, if a treating physician does
not schedule a quarterly visit, patients will have theopportunity to access the PROs at home via a Web inter-
face to decrease the amount of missing data.
Governance structure
The SystHERs steering committee provides scientific
oversight for the study and is responsible for reviewing
patient enrollment/withdrawal from the study, providing
recommendations regarding changes in study conduct,
reviewing results or interim analyses, conception of new
analyses, and participating in drafting and publishing
study reports. The steering committee comprises nine
academic and community oncologists and two breast
cancer advocates; a steering committee chair is elected
from these members annually. The steering committee
meets quarterly and operates under an approved charter,
which specifies roles and responsibilities of committee
members, as well as plans for the dissemination and
publication of data from SystHERs. The steering com-
mittee charter also describes how decisions will be made,
how study priorities will be set, and how plans will be
executed.
Statistical analysis
Continuous variables will be summarized using descrip-
tive statistics and, where applicable, analysis of variance/
model (t-test or F-test) or nonparametric testing (such
as Wilcoxon’s rank sum test [35] or Kruskal-Wallis test
[36]) will be used to test group differences. Categorical
variables will be summarized by numbers and propor-
tions, and, where applicable, chi-squared testing will be
used to test group differences. The distribution of patients,
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mens or sequences of treatment regimens for HER2-
positive MBC, will be summarized by each line of
treatment.
Comparative effectiveness end points will be analyzed
using standard statistical methods for cohort studies.
Time-to-event end points will be summarized by the
Kaplan-Meier method [37], and multivariate Cox regres-
sion analysis [38] will be performed to identify factors
associated with these end points. Inverse probability
weighted Kaplan-Meier estimates will be conducted as a
sensitivity analysis for time-to-event end points. Poten-
tial confounders will be identified and controlled for, as
appropriate, using analytical methods such as stratifi-
cation, matching, multivariable regression modeling,
and/or propensity score. A Cox proportional hazards
model [38] with a time-dependent definition for treat-
ment exposure will be used when survival bias is sus-
pected. PRO end points will be summarized by quarterly
study visit and will be analyzed using a mixed-effects
model framework.
Incidence rates of SAEs, selected AEs, AEs causing
treatment discontinuation/modification, and AEs of spe-
cial interest (eg, pregnancies and STIAMP) will be sum-
marized for all patients and by treatment regimen and
treatment sequence in terms of the proportion of pa-
tients experiencing these outcomes and as incidence
rates (events per 100 patient-years at risk). Exploratory
analyses using logistic regression may be performed to
identify risk factors for safety end points.
The planned sample size of 1000 patients was chosen
to provide a sufficient number of patients to characterize
treatments and measure overall trends by subgroups
of common treatment regimens in a broad population.
This sample size was determined to optimize the pre-
cision of measuring median survival outcomes based
on assumed median OS and PFS times obtained from
trastuzumab clinical trial data [39] and the registHER
study. The sample size was also calculated to provide
sufficient “exposed” and “control” patients to detect
survival differences between treatment regimens, on the
basis of currently available data on treatment regimen
utilization and PFS and OS estimates obtained from tras-
tuzumab clinical trial data [39] and the registHER study
[Genentech, data on file].
Discussion
The treatment options for patients with HER2-positive
MBC have changed dramatically in the last decade, and
real-world data are lacking on the natural history, treat-
ment patterns, and outcomes in the era of second and
third generation anti-HER2 therapies. SystHERs will
provide data to address this need, and the inclusion of
PROs and a biorepository will provide further insight.Lessons learned from registHER have informed the de-
sign of SystHERs, such as fewer sites (with more patients
at each site) and a longer follow-up period (at least 5 years
versus a 3-year median follow-up in registHER). registHER
was not able to fully capture data on the patient population
with survival times longer than 3 years; for example, me-
dian OS for patients <65 years of age who had received
first-line trastuzumab was 40.4 months [20]. Understand-
ing the characteristics of these patients with longer survival
times is of keen interest.
Other important differences between SystHERs and
registHER are the inclusion of a comprehensive panel
of PROs and quantification of healthcare resource
utilization. PROs capture information directly from the
patient, without modification or interpretation by an
investigator [40]. Collecting PROs empowers patients
to report health-related outcomes associated with their
treatment or illness. Completing PRO questionnaires on
a regular basis reduces recall bias and allows a broader
perspective of patient experience over time and may pro-
vide a more accurate assessment of patients’ symptoms.
Longitudinal data on the impact of multiple successive
treatment regimens on PROs are scarce. Building on the
design of the PRO substudy in the VIRGO Metastatic
Breast Cancer Registry, a US-based observational cohort
study that followed more than 1200 women with pri-
marily HER2-negative locally recurrent breast cancer or
MBC [41], SystHERs is designed to provide a compre-
hensive PRO assessment with high patient adherence.
This level of PRO assessment in an MBC registry study is
unique to SystHERs and may provide valuable informa-
tion regarding the experience of patients with HER2-
positive breast cancer receiving treatment for metastatic
disease and help patients and their clinicians make more
informed treatment choices. The SystHERs protocol ini-
tially included the PRO-CTCAE (patient-reported out-
comes version of the CTCAE) [42], but this instrument
was eliminated during a protocol amendment since there
are eight other PRO assessments and linking PRO-
CTCAE results to specific treatments was judged to
be infeasible in an observational registry with no mandated
regimen or treatment schedule.
Another distinguishing feature of SystHERs is the es-
tablishment of a repository of tissue samples with the
corresponding clinical outcomes data. This resource will
permit future correlative studies with clinical outcomes
to help tailor individualized treatment strategies in the
future. In particular, it is anticipated that future studies
will evaluate correlations of germline DNA characteris-
tics and molecular events within the tumor with clinical
outcomes, and identify inherited and somatic biomarkers
that drive tumor progression, therapeutic responses, de-
velopment of resistance, or predispositions for specific
treatment toxicities.
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Enrolling 1000 patients with recently diagnosed HER2-
positive MBC may be challenging since, due to the wide-
spread use of adjuvant trastuzumab, fewer patients with
HER2-positive early-stage breast cancer develop metas-
tases. This may result in slow accrual of patients to the
study. To address this, the planned enrollment period
for the SystHERs registry is 3 years and will be expanded
to include 146 sites with large patient populations
(ie, those expected to enroll ≥10 patients in 3 years; ap-
proximately one patient per quarter) that are intended
to be representative of the US population. SystHERs
also has broad inclusion criteria and minimal exclusion
criteria to enable the enrollment of a patient population
reflective of the clinical practice setting. A potential
limitation to the biobank is that submission of tissue
and blood samples is optional and this may impact the
exploratory analyses performed in the future.
The increasing complexity of therapeutic choices poses
another challenge to the study design and analysis plan.
The breadth of combinations of therapies, various se-
quencing patterns of therapies, and changes in available
targeted therapies over the course of the study will make
the grouping of types of treatments for analysis more
difficult. This could potentially result in small patient
numbers per group, reducing the statistical power to
compare treatment outcomes. However, in this observa-
tional study, the primary objective is to describe the dis-
tribution of patients receiving unique treatment regimens
or sequences of treatment regimens, rather than to per-
form direct comparisons between therapies. Comparative
outcomes will be made along more general lines (eg, com-
bination versus single-agent therapy with HER2-targeted
agents and chemotherapy versus targeted therapy alone)
and may inform future trials.
The large number of PRO measures being collected
may reduce completion rates due to “questionnaire fa-
tigue,” thereby increasing the amount of missing data.
However, completion of the PRO scales will take just
25 minutes every quarter and some patients will not
complete all questionnaires (eg, those without alopecia
or not working), thus reducing the average time to
complete the PROs. In addition, patients will be appro-
priately compensated for completing the questionnaire.
These two factors should increase the likelihood of com-
pletion. In an effort to relax the underlying assumptions
regarding missing data type, a likelihood-based mixed-
effects model approach rather than a single imputation
approach, such as last observation carried forward, will
be used for the PRO analysis.
Investigators will not be required to use Response
Evaluation Criteria in Solid Tumors (RECIST) to deter-
mine secondary efficacy end points. These end points
will instead be assessed according to standard clinicalpractice at each institution. This approach has been
adopted to capture the typical real-world experience of
patients with MBC for whom the evaluation of tumor
response may not be conducted in accordance with pre-
defined criteria, such as the objective RECIST response
criteria typically employed in oncology clinical trials. A
drawback of this approach is the potential for variation
between investigators and between study sites in how
response is evaluated. However, investigators are en-
couraged to document their response assessment methods;
thus, variations in assessment methodology can be investi-
gated retrospectively. AEs will be reported in SystHERs in
a similar manner to how they are reported in clinical trials.
While offering a uniform approach between clinicians and
across study centers, this approach may not best reflect the
real-world experience of MBC patients in routine oncology
practice. Additionally, patients enrolled in SystHERs may
simultaneously be enrolled in a blinded randomized con-
trolled trial; thus the study treatment received by the pa-
tients may not be known until after the trial is unblinded.
Future directions
With a 3-year enrollment period and an additional
5 years of follow-up, SystHERs is well positioned to cap-
ture changes to the targeted treatment of HER2-positive
MBC treatment resulting from ongoing clinical studies
of emerging therapies and of combination treatment
with existing therapies. Phase III trials are underway in-
vestigating the clinical impact of concomitant treatment
with agents targeting multiple HER-family proteins, such
as trastuzumab plus lapatinib and T-DM1 plus pertu-
zumab [43]. Investigations into combined HER-family
blockade will increase as new HER2–HER4 multi-kinase
inhibitors, such as afatinib and neratinib (which also in-
hibits EGFR), advance into late-stage trials [43]. There is
also interest in combining HER2-targeted therapies with
agents that inhibit signaling molecules downstream of
HER-family receptors, such as PI3K, Akt, and mTOR. A
phase III trial has demonstrated modest benefit for
trastuzumab and vinorelbine plus the FDA-approved
mTOR inhibitor everolimus in patients with trastuzumab-
insensitive, HER2-positive MBC.[43] Early-stage trials seek
to evaluate treatment with trastuzumab or lapatinib in
combination with investigational inhibitors of PI3K or Akt
[43]. By including clinical trial participants, SystHERs may
provide early insight into the safety and efficacy of combin-
ation treatment with HER2-targeted therapies and some of
these investigational agents.
Moreover, SystHERs has the potential to elucidate on-
going trends in patient selection for HER2-targeted ther-
apy and to provide additional insight into the factors
that predict clinical benefit from HER2-targeted therapy.
SystHERs allows patients to donate tumor and blood
samples for future study.
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The SystHERs registry aims to capture key characteris-
tics of patients with HER2-positive MBC at or near to
the time of their diagnosis and then follow them pro-
spectively to gather information on the treatments they
receive and the corresponding outcomes. This will allow
quantitative, descriptive, and comparative analyses, which
will evaluate associations between risk factors, treatments,
and outcomes. Preliminary descriptive data based on initial
enrollees is expected in late 2014. As a longitudinal obser-
vational cohort study, SystHERs will provide insight into
the evolving treatment landscape of HER2-positive meta-
static breast cancer.
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